The 12th International Conference on Biomedicine and Pharmaceutices (ICBP2024) will be held on September 26, 2024 in Zhengzhou, China. The Conference is organized by International Association of Management Science & Engineering Technology (IAMSET).
    ICBP2024 aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Biomedicine and Pharmaceutices. It also provides a premier interdisciplinary platform for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns as well as practical challenges encountered and solutions adopted in the fields of Biomedicine and Pharmaceutices. With its high quality, it provides an exceptional value for students, academics and researchers.


Drug Discovery and Development
  • Drug Design
  • Pharmaceutical Formulation
  • Pharmaceutical Process
  • Lead Generation
  • Target Identification and Validation
  • Simulation Approaches in Drug Development
  • Pharmaceutical Transformation Quality
  • In-Vitro and in-Vivo Performance Testing
  • Pharmacogenetics and Pharmacogenomics
Drug Delivery and Translation
  • Antibody Targeting
  • Protein/Peptide Delivery
  • Image-guided Drug Therapy
  • Modes of Drug Entry
  • Drug Delivery Systems and Biocompatibility
  • DNA, Oligonucleotide and siRNA Delivery
  • Microcapsules, Liposomes, Vesicles and Macromolecular Conjugates
  • Devices for Drug Delivery and Drug/Device Combination Products
  • Therapeutic Drug Monitoring
  • Drug Absorption and Disposition
  • Metabolism and Excretion of Drugs
  • Drug Transporters
  • Pharmacokinetics and Pharmacodynamics
  • Toxicokinetics and Toxicodynamics
  • Drug-drug Interactions and Enzyme Kinetics
  • Application of Machine Learning to Pharmacokinetics-pharmacodynamics
Drug Safety and Toxicity
  • Drug-drug Interactions
  • Adverse Drug Reactions
  • Mechanisms of Drug Toxicity
  • Pharmacovigilance
  • Drug Safety Evaluations
  • Safety in 'At-risk' Patient Populations
  • Risk Analyses of Drugs and Drug Classes